Le Lézard
Classified in: Health
Subjects: NPT, CHI, AVO, FVT

Children's Health Advocates Gather to Demand Truth and Justice for the Vaccine-Injured


WASHINGTON, Nov. 12, 2019 /PRNewswire/ -- Thousands of advocates for children's health will gather Thursday at the Vaccine Injury Epidemic (VIE) Event on the National Mall to mark the 33rd anniversary of National Childhood Vaccine Injury Act (NCVIA). The rally on Nov. 14th will spotlight the devastating impact NCVIA has had upon the state of children's health. Vaccine makers cannot be held accountable, thereby eliminating any incentives for improved vaccine safety.  

RFK, Jr. will address the ramifications of NCVIA and honor those whose lives have been forever changed by vaccines. "It's time to call out Congress, the CDC, and drug companies for allowing industry profits to trump children's [potential] health [risks]," said Kennedy. "There is no crisis more urgent than the epidemics of chronic health conditions among our nation's children."

Following NCVIA's passage creating the National Vaccine Injury Compensation Program (NVICP), the childhood vaccine market sparked a gold rush for Pharma as more vaccines for routine childhood illnesses were developed. Coterminous with the burgeoning vaccine schedule, chronic health conditions in children rose from 12% to 54%.  As vaccine industry profits grew to $50 billion annually, so did diagnoses of asthma, autism, ADHD, allergies, anxiety, depression, diabetes, obsessive-compulsive disorder and auto-immune diseases. Here are the facts:

Children's Health Defense's six steps to vaccine safety. RFK, Jr. interviews upon request. 

Contact: Laura Bono 202-854-1310

SOURCE Children's Health Defense


These press releases may also interest you

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

at 17:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...

at 16:30
Viatris Inc.  will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the...

at 16:30
WELL Health Clinic Network Inc. ("WELL"), a subsidiary of WELL Health Technologies Corp. , a digital healthcare company focused on...

at 16:25
Precision BioSciences, Inc. , an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain...



News published on and distributed by: